KLOW
GHK-Cu + BPC-157 + TB-500 + KPV research blend
Four-peptide research blend combining GHK-Cu, BPC-157, TB-500 and KPV; the evidence base belongs to the individual components rather than the co-formulation.
Reference dose
1.6–4.8 mg per injection
Source-specific educational reference, not an individualized recommendation.
Reference schedule
Daily initially, then 5×/week, then 2–3×/week in the cited 12-week protocol · 12 weeks
New to peptide research?
This page gets detailed quickly.
Profiles include evidence, formats, units, source-specific reference amounts and, where relevant, device details. If any of those terms are unfamiliar, do not guess your way through them. Start with a Personalised Guide and we will put the foundations in the right order for you.
At a glance
Components
4 peptides
GHK-Cu + BPC-157 + TB-500 + KPV.
Blend-level trials
None identified
Evidence is derived from individual components.
Standard formula
No
Commercial component ratios can differ.
Human evidence
Not for KLOW
Human findings for individual components do not validate the four-way blend.
What it is
KLOW is a vendor/community blend name for a multi-peptide vial containing GHK-Cu, BPC-157, TB-500 and KPV.
The four ingredients remain distinct molecules with distinct evidence bases; the blend name does not create a new clinically characterized compound.
Research focus
How it works
KLOW combines four separate peptides associated with different research themes: GHK-Cu with extracellular-matrix biology, BPC-157 and TB-500 with tissue-repair research, and KPV with preclinical anti-inflammatory signalling. The combination has not established its own pharmacology or clinical effect.
Important context
KLOW is not a standardized drug formula. The addition of KPV to a GLOW-like blend broadens the proposed research rationale, but it does not create evidence for the four-way combination. Component findings must remain attributed to the component that generated them.
What it is studied for
Skin and matrix interest is inherited primarily from GHK-Cu research.
Recovery interest is inherited primarily from BPC-157 and thymosin-beta-4-related research.
KPV adds a preclinical inflammatory and intestinal-barrier research theme, which is the main conceptual difference from GLOW.
More contextThe KPV addition changes the hypothesis, not the evidence standardSee the deeper context, evidence details and practical distinctions behind this profile.
KPV adds a distinct preclinical anti-inflammatory research theme involving intestinal transport and inflammatory signalling. FDA reports no identified human drug-exposure data for KPV.
GHK-Cu, BPC-157 and TB-500 retain the same evidence limitations they have outside the blend. No controlled four-component trial was identified for this profile.
- KLOW formulations and mass ratios vary across commercial research products.
- No validated blend pharmacokinetics, dose-response relationship, compatibility dataset or human safety dataset is established.
- The strongest direct human evidence among the components is route-specific GHK-Cu topical research; that should not be generalized to injected KLOW.
- BPC-157, TB-500 and KPV were all part of FDA's July 2026 503A compounding review, while FDA separately flags injectable GHK-Cu safety concerns.
Why people are interested
What makes KLOW worth researching.
Component · human topical + preclinical
GHK-Cu arm
Provides the strongest direct human evidence in the blend, but mainly from topical skin studies involving collagen and wrinkle-related outcomes.
Component · mostly preclinical
BPC-157 / TB-500 arms
These drive much of the recovery rationale, but the direct human evidence is sparse for BPC-157 and absent or indirect for the TB-500 fragment.
Component · preclinical
KPV arm
Cell and animal studies support interest in anti-inflammatory and intestinal signalling, but FDA reports no identified human drug-product exposure data.
Blend evidence absent
Four-way blend
No controlled evidence establishes additive benefit, pharmacokinetics, safety or an optimal ratio for the four components when co-formulated.
Evidence
Where the evidence is strongest, and what kind of evidence it is.
GHK-Cu component evidence
Skin / matrix biology
Small topical human studies and preclinical research support GHK-Cu interest, but route and formulation are critical and do not validate injected KLOW.
BPC-157 + TB-500 component evidence
Recovery biology
Preclinical repair literature exists for both research areas, with major limitations in direct human evidence and in assigning full-length thymosin-beta-4 findings to TB-500.
KPV component evidence
Inflammation / gut biology
KPV has cell and animal evidence involving PepT1, NF-κB and experimental colitis, but no established human clinical treatment evidence.
No controlled blend evidence identified
KLOW co-formulation
There is no established clinical dose, validated component ratio, blend pharmacokinetic profile or human safety dataset.
Human research
No controlled human trial of the four-component KLOW blend was identified for this profile.
Human evidence among the components is highly uneven and route-specific, ranging from topical GHK-Cu studies to very limited BPC-157 pilot data and no identified human drug-exposure data for KPV or TB-500.
It is not valid to aggregate those separate literatures into a clinical claim for the KLOW blend.
Preclinical research
All four components have separate laboratory or animal research relevant to one or more proposed blend themes.
No direct study of all four co-formulated components was identified for this profile.
There is no established evidence that adding KPV improves, worsens or leaves unchanged the effects of the three-component GLOW-style combination.
Reference dosing
Reference amount, schedule and conversion.
A reference amount is only useful when you know the formulation, concentration and delivery device it belongs to. Do not transfer a vial amount into a pen, a pen click count into another pen, or a syringe-unit number into a different concentration.
01
Identify the format
Vial, reusable cartridge pen, prefilled multi-dose pen or single-dose autoinjector.
02
Confirm concentration
Know the total peptide amount and liquid volume or the manufacturer/vendor concentration.
03
Understand the units
Keep mg/mcg, mL and syringe units or device clicks separate.
04
Then use the reference
Only convert a known reference amount with the calculator that matches the actual device.
Source-specific reference
1.6–4.8 mg per injection
Daily initially, then 5×/week, then 2–3×/week in the cited 12-week protocol · 12 weeks
The range above is The Pep Report research reference for KLOW. KLOW is a multi-peptide blend, so the exact component ratio and formulation still matter.
Calculator connection
This profile does not currently use a vial or pen calculator. Follow the formulation-specific information shown for the product or reference you are using.
The same total vial mass can represent very different amounts of GHK-Cu, BPC-157, TB-500 and KPV. A single-mass vial calculator would therefore hide the information needed for component-level arithmetic and is intentionally disabled.
Storage
Start with the format. Then verify the exact product.
Rule of thumb, not a product instruction
Storage belongs to the exact formulation. Generic advice can orient you, but the label, pharmacy directions or formulation-specific stability data should determine the final temperature and usable-life limits.
Pens
Treat a pen as a finished drug-device product: protect it from unnecessary heat and light, do not freeze unless the exact label explicitly permits it, and use that device's own unopened and in-use storage window.
Vials
Treat dry and reconstituted vials as different stability states. Refrigeration after mixing is common for some formulations but is not a universal peptide rule.
Product-specific notes
There is no approved KLOW label establishing standardized storage or shelf-life conditions.
Four-component co-formulation stability can depend on exact peptide forms, ratio, excipients, pH and handling.
Practical reference
Formats
Multi-peptide blend vial
Reconstitution & units
Adding liquid changes all four component concentrations simultaneously.
Meaningful arithmetic requires the exact mass of GHK-Cu, BPC-157, TB-500 and KPV in the vial, not just the total mg printed on the front.
The generic vial calculator is disabled because it handles one peptide mass rather than four component masses.
A future blend-specific calculator should calculate each component independently from the exact labelled composition.
Safety, status & open questionsOpen the practical cautionsKLOW is a research blend designation, not an FDA-approved medicine. There is no controlled evidence that adding KPV to GHK-Cu + BPC-157 + TB-500 produces a clinically useful anti-inflammatory, healing or skin effect in humans.
Open questions
KLOW is not standardized, so vendor-specific component ratios can change both concentration arithmetic and the biological hypothesis.
Blend compatibility, stability and pharmacokinetics have not been clinically characterized.
The human safety consequences of exposing a person to all four components together are unknown.
Claims about synergy are mechanistic extrapolations unless and until direct combination studies test them.
Regulatory notes
KLOW is not an FDA-approved medicine or standardized pharmaceutical formulation.
BPC-157-related, KPV-related and TB-500-related substances were reviewed in FDA's July 2026 503A compounding process.
FDA separately identifies injectable GHK-Cu among compounded bulk substances that may present significant safety concerns.
Practical notes
There is no direct human safety dataset for the four-way KLOW blend.
Each component carries its own evidence and safety uncertainties, and co-formulation does not remove them.
FDA has raised safety or characterization concerns relevant to injectable GHK-Cu and has separately reviewed BPC-157, KPV and TB-500-related bulk substances.
Research/compounded injectable products also add risks around identity, purity, sterility, concentration and formulation stability.
Common mistakes
Treating KLOW as a standardized pharmaceutical product.
Adding up component evidence and calling it blend evidence.
Using KPV animal colitis findings to claim proven human anti-inflammatory benefit from KLOW.
Using topical GHK-Cu studies to support injected KLOW skin claims.
Calculating a total blend dose without knowing the exact four-component ratio.
Common questions
What is the difference between KLOW and GLOW?
KLOW generally adds KPV to a GLOW-style combination of GHK-Cu, BPC-157 and TB-500. Neither name represents a standardized approved formulation.
Has KLOW been tested as a four-peptide blend?
No controlled human or direct four-component study was identified for this profile. The evidence comes from the ingredients separately.
Does KPV make KLOW a proven anti-inflammatory treatment?
No. KPV's anti-inflammatory evidence is preclinical, and FDA reports no identified human drug-product exposure data for KPV.
Why is the vial calculator disabled?
Because total vial mg is not enough. The exact mass of all four components is required to calculate component-level concentrations without hiding the blend ratio.
Related peptides & blends
GLOW
Vendor/community blend name for a co-formulation of GHK-Cu, BPC-157 and TB-500; evidence comes from the individual components rather than the three-peptide blend itself.
Open reference →GHK-Cu
Naturally occurring copper-binding tripeptide researched for collagen signalling, skin quality, extracellular-matrix remodelling and tissue repair.
Open reference →BPC-157
Synthetic 15-amino-acid peptide with extensive animal research in tissue-repair and gastrointestinal models but very limited human evidence.
Open reference →TB-500
Synthetic thymosin-beta-4-related fragment researched for wound and tissue-repair biology, with no established human clinical evidence for the fragment itself.
Open reference →KPV
Melanocortin-derived tripeptide studied for anti-inflammatory effects in cell and animal models, with no established human drug-exposure data.
Open reference →BPC-157 / TB-500 (Wolverine)
Research blend name for BPC-157 + TB-500; one 2026 rat tendon study tested the combination directly, but no controlled human blend trial has established efficacy or dosing.
Open reference →References
KPV and intestinal inflammation — PepT1-mediated preclinical study
Gastroenterology / PubMed · 2008
GHK-Cu topical anti-wrinkle evidence — review
BioImpacts / PMC · 2025
BPC-157 human IV safety pilot
PubMed · 2025
FDA July 2026 PCAC review — BPC-157, KPV and TB-500-related substances
U.S. FDA · 2026
FDA — compounded bulk substances that may present significant safety risks
U.S. FDA · 2026
BPC-157 in orthopaedic sports medicine — systematic review
PMC · 2025